Erschienen in:
01.04.2007 | Original Article
Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis
verfasst von:
Gloris Sánchez, Julio S. Castro, Soham Al Snih, Luísa Pérez Blanco, María H. Esteva, Ernesto García MacGregor, Marielena González, Ysabel Granados, Francisco Marín, Alexis Rosas, Antonio Tristano, Esther Chirinos, Luís Mundaraín, Gilberto Sanoja, Guisela Zambrano-Marín, Martín A. Rodríguez
Erschienen in:
Rheumatology International
|
Ausgabe 6/2007
Einloggen, um Zugang zu erhalten
Abstract
A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92% at 12 months to 42% at 180 months, as assessed by life table analysis and the Kaplan–Meier method. Forty-seven patients stopped treatment and adverse effects (29.7%) and lack of continuous access to medication (19.1%) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.